Published in J Neurol Neurosurg Psychiatry on January 01, 1996
Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management. J Inherit Metab Dis (2011) 1.49
Clinical heterogeneity and prognosis in combined methylmalonic aciduria and homocystinuria (cblC). J Inherit Metab Dis (1997) 1.35
Cobalamin C defect: natural history, pathophysiology, and treatment. J Inherit Metab Dis (2010) 1.28
Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes. J Inherit Metab Dis (2011) 1.06
Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. Orphanet J Rare Dis (2014) 0.93
Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis (2016) 0.75
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Mammalian TOR: a homeostatic ATP sensor. Science (2001) 6.41
Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med (1991) 6.03
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A (1997) 4.70
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest (1994) 3.58
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Botulinum toxin for palmar hyperhidrosis. Lancet (1997) 3.17
Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect (1999) 3.07
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med (1985) 2.49
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis. N Engl J Med (1996) 2.38
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry (1989) 2.29
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Striatal grey matter increase in patients suffering from fibromyalgia--a voxel-based morphometry study. Pain (2007) 2.18
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
Long-term outcome after thrombolysis in telemedical stroke care. Neurology (2007) 2.12
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 2.12
A role for BDNF in mechanosensation. Nat Neurosci (1998) 2.08
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology (2010) 2.04
Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet (1999) 1.99
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93
Self glycolipids as T-cell autoantigens. Eur J Immunol (1999) 1.93
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol (1993) 1.92
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Myasthenia gravis: passive transfer from man to mouse. Science (1975) 1.90
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics (1997) 1.86
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol (1998) 1.83
Affective components and intensity of pain correlate with structural differences in gray matter in chronic back pain patients. Pain (2006) 1.83
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler (2002) 1.80
Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology (2010) 1.80
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.77
Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology (1995) 1.77
Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler (2001) 1.76
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology (2011) 1.75
Quality of life following radiofrequency ablation of dysplastic Barrett's esophagus. Endoscopy (2010) 1.75
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity (2000) 1.72
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
Gray matter decrease in patients with chronic tension type headache. Neurology (2005) 1.71
Perioperative management of a child with very-long-chain acyl-coenzyme A dehydrogenase deficiency. Paediatr Anaesth (2002) 1.70
Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci U S A (1996) 1.68
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis (1979) 1.67
Exercise for intermittent claudication. Cochrane Database Syst Rev (2000) 1.66
The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler (2009) 1.65
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65
Prednisone in Duchenne muscular dystrophy. Lancet (1974) 1.65
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature (1984) 1.63
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology (1990) 1.61
Linkage of proximal myotonic myopathy to chromosome 3q. Neurology (1999) 1.60
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet (1995) 1.60
Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol (1998) 1.60
Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler (2006) 1.60
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev (2001) 1.59
Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis (2009) 1.58
Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.57
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology (1997) 1.55
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology (2003) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53
Five patients with a biotin-responsive defect in holocarboxylase formation: evaluation of responsiveness to biotin therapy in vivo and comparative biochemical studies in vitro. Pediatr Res (1997) 1.53
Early natural course of transient encephalopathy after coronary artery bypass grafting. Crit Care Med (2000) 1.52
Clinical and neuropsychological outcome in 33 patients with biotinidase deficiency ascertained by nationwide newborn screening and family studies in Austria. Eur J Pediatr (2001) 1.50
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002]. Nervenarzt (2002) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve (2000) 1.50